Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: A pilot study.

@article{DeaunaLimayo2014CombinedUO,
  title={Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: A pilot study.},
  author={Delva P. Deauna-Limayo and Omar S Aljitawi and Siddhartha S. Ganguly and Sunil H Abhyankar and Jo A. Wick and J P Mcguirk},
  journal={Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners},
  year={2014},
  volume={20 4},
  pages={
          263-9
        }
}
BACKGROUND The current standard for prevention of chemotherapy-induced nausea/vomiting in autologous stem cell transplant only achieves 4-20% emetic control. OBJECTIVES To assess emetic responses to multiday palonosetron, aprepitant, and low-dose dexamethasone among patients with myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant. METHODS Oral aprepitant 125/80/80 mg was administered with intravenous dexamethasone 4 mg and palonosetron 0.25 mg on days -3, -2, -1… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS